Sepsis Diagnostics Market Size To Reach $1.82 Billion By 2030

Sepsis Diagnostics Market Growth & Trends

The global sepsis diagnostics market size is expected to reach USD 1.82 billion by 2030, registering a CAGR of 8.09% from 2025 to 2030, according to a new report by Grand View Research, Inc. The high prevalence of sepsis, the introduction of technologically advanced diagnostic systems, and increasing government initiatives are expected to propel market growth over the forecast period. Sepsis is a bloodstream disease that occurs as a result of a response to pathogenic microorganisms present in the blood. Patients suffering from this disease experience severe inflammation, which leads to prolonged hospitalization.

According to the WHO, around 30 million people are estimated to be affected by this disease every year. The NCBI stated that the largest number of this condition have been observed in the youngest and oldest age groups. Thus, there is a rising need for the early diagnosis of this disease. The WHO reported that every year, 1.2 million children and 3 million newborns are affected by this disease across the world. This has further boosted the demand for its diagnostic tools for quick results and improved patient outcomes. Increasing regulatory approval and the introduction of technologically advanced diagnostic solutions for sepsis are expected to facilitate market growth over the forecast period.

In May 2018, T2 Biosystems, Inc., a U.S.-based emerging diagnostic solutions company, received the U.S. FDA approval for its T2Bacteria Panel, intended for the detection of specific sepsis-causing bacterial pathogens in human whole blood specimens. The COVID-19 pandemic affected the growth of diagnostics products for sepsis in a moderately positive way. The worldwide spread of Coronavirus and the arising instances of sepsis among COVID-19 patients are probably going to expand the interest for fast detection, speeding up the use of instruments, reagents, and assay kits for recognition of sepsis. Pandemic-induced lockdown and other restrictions made individuals delay going through wellbeing checkups, influencing the number of tests performed and reagent deals.

The pandemic has featured the risk upon elders, who are more defenseless to complications, including intense respiratory distress condition, typically because of pneumonia, which builds the risk of creating sepsis. This has created a need for the early detection of sepsis among patients with COVID-19. Symptoms of sepsis, such as multiorgan injuries, develop in around 2.0 to 5.0% of COVID-19 cases 8 to 10 days post-hospitalization, based on the estimates of the Global Sepsis Alliance. To manage this situation, the Biomedical Advanced Research and Development Authority, in May 2020, extended its partnership with Beckman Coulter for the development of a digital algorithm to detect sepsis in patients with COVID-19.

 Request a free sample copy or view the report summary: Sepsis Diagnostics Market Report

Sepsis Diagnostics Market Report Highlights

• Based on product, blood culture media dominated the market in 2024 with a revenue share of more than 38.90%, as blood culture is considered to be the most cost-effective and convenient mode of testing.

• The microbiology technology segment dominated the global market in 2024 and accounted for the largest share of more than 48.77% of the overall revenue.

• Bacterial segment held the largest revenue share of 86.22% in 2024 and is anticipated to maintain its lead over the forecast period owing to the rise in cases of bacterial sepsis, higher occurrence of hospital-transmitted infections, and rising number of surgical procedures conducted.

• The conventional diagnostics segment held the largest revenue share of 57.12% of the sepsis diagnostics industry in 2024.

• The hospital and clinics segment held the largest revenue share of 79.42% in 2024, owing to an increase in hospitalization.

• The laboratory testing segment dominated the market in 2024 in terms of revenue share. Advancements in laboratory testing have made it easier and faster to detect sepsis, leading to better outcomes for patients.

• North America sepsis diagnostics market dominated globally in 2024 and accounted for the largest revenue share of more than 43.9%.

Sepsis Diagnostics Market Segmentation

Grand View Research has segmented the sepsis diagnostics market on the basis of on product, method, end-use, technology, pathogen, testing, and region:

Sepsis Diagnostics Product Outlook (Revenue, USD Million, 2018 - 2030)

• Instruments

• Blood Culture Media

• Assay Kits and Reagents

• Software

Sepsis Diagnostics Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Microbiology

• Molecular Diagnostics

  • Polymerase Chain Reaction (PCR)

  • DNA Microarrays

  • Syndromic Panel testingOthers

• Immunoassays

• Flow Cytometry

• Others

Sepsis Diagnostics Pathogen Outlook (Revenue, USD Million, 2018 - 2030)

• Bacterial Sepsis

  • Gram-positive Bacteria

  • Gram-negative Bacteria

• Fungal Sepsis

• Viral Sepsis

• Others

Sepsis Diagnostics Testing Outlook (Revenue, USD Million, 2018 - 2030)

• Laboratory Testing

• PoC Testing

Sepsis Diagnostics Method Outlook (Revenue, USD Million, 2018 - 2030)

• Automated Diagnostics

• Conventional Diagnostics

Sepsis Diagnostics End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals & Clinics

• Pathology & Reference Laboratories

• Research Institutes and Others

Sepsis Diagnostics Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • Germany

  • UK

  • Spain

  • France

  • Italy

  • Russia

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • South Korea

  • Singapore

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Mexico

  • Argentina

• MEA

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Sepsis Diagnostics Market

• BD

• bioMérieux SA

• Thermo Fisher Scientific, Inc.

• Danaher Corporation (Beckman Coulter, Inc.)

• F. Hoffmann-La Roche AG

• Cepheid

• Luminex Corp.

• Koninklijke Philips N.V.

• Bruker

• Immunexpress, Inc.